2026-04-29T12:23:38Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/78272024-11-29T14:39:17Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597

00925njm 22002777a 4500 dc Sánchez, Ricardo author Ayala, Rosa author Martinez-Lopez, Joaquin author 2019-06-10 Ultra-deep next-generation sequencing has emerged in recent years as an important diagnostic tool for the detection and follow-up of tumor burden in most of the known hematopoietic malignancies. Meticulous and high-throughput methods for the lowest possible quantified disease are needed to address the deficiencies of more classical techniques. Precision-based approaches will allow us to correctly stratify each patient based on the minimal residual disease (MRD) after a treatment cycle. In this review, we consider the most prominent ways to approach next-generation sequencing methodologies to follow-up MRD in hematological neoplasms. Int J Mol Sci. 2019;20(11). pii: E2832. 10.3390/ijms20112832 1422-0067 1422-0067 International journal of molecular sciences 31185671 http://hdl.handle.net/20.500.12105/7827 clonal evolution hematological neoplasms high-throughput sequencing minimal residual disease next-generation sequencing Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies